http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017044233-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0cf33ac8aef4f0d056ef74ec67596d29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e67b860765e2351a2fbf5649af5fba70 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-725 |
| filingDate | 2016-07-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_350fefd9f8b67cf288939a9f459c0ad0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4ddb916ae7b5abef3160681df93533d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89a93acd331d0eb1e11a1fcd0bc07a43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_958a76a28f89821987370d9fda181eaa |
| publicationDate | 2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2017044233-A1 |
| titleOfInvention | Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof |
| abstract | The present invention is directed to a kit-of-parts or composition containing nucleic acid sequences coding for high-avidity, allo-restricted TCR, wherein the TCR are independently directed against the tyrosinase antigen, the melan-A antigen and the survivin antigen. The invention is further directed to a kit-of-parts or composition containing at least three groups of transgenic lymphocytes transformed with vectors coding for TCR against said antigens. Furthermore, the present invention provides a pharmaceutical composition and its use in the treatment of diseases involving malignant cells expressing said tumor-associated antigens. The invention further relates to a nucleic acid molecule coding for a TCR that recognizes the survivin antigen, a TCR encoded thereby and a T cell expressing said TCR. Further, the invention discloses a vector, a cell and a pharmaceutical composition encoding/containing same and their use in the treatment of diseases involving malignant cells expressing survivin. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014348805-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9862755-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018162921-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626159-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020339653-A1 |
| priorityDate | 2009-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 177.